# Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment

> **NCT02873936** · PHASE3 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 449 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Filgotinib
- **DRUG:** Placebo to match filgotinib
- **DRUG:** csDMARDs

## Key facts

- **NCT ID:** NCT02873936
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07-27
- **Primary completion:** 2018-03-20
- **Final completion:** 2018-06-26
- **Target enrollment:** 449 (ACTUAL)
- **Last updated:** 2021-05-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02873936

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02873936, "Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02873936. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*